INCIVEK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INCIVEK (INCIVEK).
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
| Metabolism | Hepatic via CYP3A4; also substrate of P-glycoprotein and OATP1B1. |
| Excretion | Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug). |
| Half-life | Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients. |
| Protein binding | Approximately 97-99% bound to human plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution (Vd/F) is 750 L (approx. 10.7 L/kg for a 70 kg individual) indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is not determined due to lack of intravenous formulation; food increases exposure by 2-3 fold (taken with meals). |
| Onset of Action | Rapid reduction in HCV RNA is observed within 24 hours after oral administration; maximal effect on viral load occurs by day 3. |
| Duration of Action | Duration of action is 24 hours due to thrice-daily dosing; steady-state achieved by day 7. Clinical effect maintained throughout dosing interval. |
| Molecular Weight | 519.6 |
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
| Dosage form | TABLET |
| Renal impairment | No dose adjustment is required for mild to moderate renal impairment (CrCl >30 mL/min). Insufficient data for severe renal impairment (CrCl ≤30 mL/min) or hemodialysis; use with caution. |
| Liver impairment | Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh Class B or C). No dose adjustment for mild hepatic impairment (Child-Pugh Class A). |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established. No recommended dosing. |
| Geriatric use | No specific dose adjustment recommended; select dose cautiously due to potential age-related decreases in renal function and comorbidities. |
| 1st trimester | Contraindicated due to teratogenic effects observed in animal studies and risk of fetal harm. |
| 2nd trimester | Contraindicated; no adequate human studies; potential for fetal harm outweighs any benefits. |
| 3rd trimester | Contraindicated; risk of fetal toxicity and adverse outcomes. |
Clinical note
Comprehensive clinical and safety monograph for INCIVEK (INCIVEK).
| Placental transfer | Boceprevir is highly protein-bound (75%) and has a molecular weight of 519.6 Da, which suggests limited placental transfer; however, animal studies have shown fetal toxicity and teratogenicity. Human data are insufficient to assess placental transfer. |
| Breastfeeding | Not recommended during breastfeeding due to potential for serious adverse reactions in nursing infants. It is unknown if boceprevir is excreted in human milk; however, due to its high molecular weight and extensive protein binding, excretion is likely low but safety has not been established. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to boceprevir or any component of the formulationCoadministration with drugs highly dependent on CYP3A4/5 for clearance (e.g., alfuzosin, amiodarone, colchicine, ergot derivatives, lovastatin, simvastatin, oral midazolam, pimozide, sildenafil when used for PAH, triazolam)Pregnancy (based on teratogenicity in animal studies and potential for fetal harm)
| Precautions | Anemia and neutropenia: increased risk with peginterferon alfa and ribavirin, Serious skin reactions including Stevens-Johnson syndrome and erythema multiforme, Cardiac arrhythmias, including bradycardia, in patients with hepatic impairment or taking other drugs, Use with caution in patients with hepatic decompensation |
| Food/Dietary | Take with a meal containing moderate fat (e.g., a standard lunch or dinner). Avoid low-fat meals or snacks as they reduce absorption. Grapefruit juice may increase telaprevir levels; avoid concurrent intake. |
Loading safety data…
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | INCIVEK (telaprevir) is contraindicated in pregnancy due to teratogenic effects observed in animal studies. In the first trimester, there is a risk of major birth defects; in second and third trimesters, fetal harm cannot be ruled out. Pregnancy must be excluded before initiation, and effective contraception must be used during treatment and for 6 months after last dose. |
| Fetal Monitoring | Pregnancy testing must be performed prior to initiation, during treatment (monthly), and for 6 months after discontinuation. Monitor for rash, anemia (CBC monthly), and hepatic function (AST, ALT, bilirubin every 2 weeks initially, then monthly). Fetal ultrasound if indicated. |
| Fertility Effects | Telaprevir has not been studied for effects on human fertility. In animal studies, no impairment of mating or fertility was observed at systemic exposures lower than clinical exposure. However, ribavirin component in standard regimen is known to cause reversible infertility in males and may impair female fertility. |
| Clinical Pearls | Incivek (telaprevir) is a protease inhibitor used in combination with peginterferon alfa and ribavirin for HCV genotype 1. It requires a 12-week lead-in with peginterferon/ribavirin before adding telaprevir. Monitor for severe rash, including DRESS syndrome, and anemia. Dose adjustments for ribavirin may be needed. Telaprevir is a strong CYP3A4 inhibitor and substrate; avoid coadministration with drugs highly dependent on CYP3A4 clearance. Administer with food (not low-fat) to enhance absorption. |
| Patient Advice | Take Incivek with food, not on an empty stomach, and avoid low-fat meals. · Do not stop any of your hepatitis C medications without talking to your doctor. · Report any rash immediately, especially if accompanied by fever, blisters, or mouth sores. · This drug can cause severe anemia; you will need frequent blood tests. · Incivek may interact with many other drugs; tell your doctor about all medications you take. · Use effective contraception during treatment and for 6 months after, as ribavirin can cause birth defects. · Incivek must be taken every 8 hours (three times daily) and not missed. |